Cosentyx: It’s finally here!
If you have been treating psoriatic patients for any length of time, then you have probably heard and been looking forward to the availability of the first interleukin-17A (IL-17) biologic. Secukinumab (Cosentyx by Novartis Pharmaceuticals) will become commercially available in early March and will be a treatment option for any of your moderate to severe psoriasis patients.
In the ERASURE study, approximately 82% of patients on 300 mg of secukinumab met the criteria of PASI 75 by week 12 and approximately 72% of patients on the 150 mg dose also reached PASI 75. The protocol administers a once weekly dose for 5 weeks, then every 4 weeks thereafter. The FIXTURE study compares the efficacy of secukinumab with the efficacy of etanercept. The PASI 75 rates for 300 mg of secukinumab are 77% compared to 67% for 150 mg of secukinumab and 44% for etanercept (50 mg twice weekly for 12 weeks then weekly). Both studies appear to have proven that secukinumab is certainly a viable option in your armamentarium for psoriatic patients.
The verdict is out on how secukinumab will be utilized initially and in the future. Most healthcare providers already have at least a handful of patients who they will start right away who have failed any (or all) TNF-α inhibitors. Some thought leaders predict that secukinumab (and other IL-17 inhibitors that emerge) may become the first line therapy for psoriatic patients in the next five years. That remains to be seen, although the initial safety data does look good, the long-term safety data is somewhat unknown. All the information about how to get your patients started is found at cosentyx.com.
By: Bethany Grubb, MPH, MPAS, PA-C; SDPA Diplomate; Past President
[Image: Bhopal Medical Appeal]